GPP Interview with Professor Barker GPP Interview with Professor Barker An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Interstitial lung disease in rheumatoid arthritis (RA-ILD) Interstitial lung disease in rheumatoid arthritis (RA-ILD) Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
Lothar Halmer Lothar Halmer Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
BTD for GlyT1 in Schizophrenia BTD for GlyT1 in Schizophrenia Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Launch VETMEDIN Solution oral solution congestive heart failure in dogs Launch VETMEDIN Solution oral solution congestive heart failure in dogs The new VETMEDIN® Solution offers pet owners a convenient, liquid oral treatment option for those dogs that prefer a liquid
Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Feline diabetes: how to detect and treat it Feline diabetes: how to detect and treat it What are the symptoms of diabetes in cats, and how do you manage this chronic disease? Find the answers here.
Major investment for respiratory diseases completed Major investment for respiratory diseases completed 105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
FOYA_Shanghai FOYA_Shanghai Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Human-dog relationship – a historical perspective Human-dog relationship – a historical perspective The human-dog relationship – a historical perspective
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
FDA-CRL-T1D FDA-CRL-T1D US FDA issues complete response letter for treatment of adults with type 1 diabetes
Production Insights Production Insights Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Supporting Fundappas Supporting Fundappas Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
opening-solids-launch-fabrik opening-solids-launch-fabrik Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Boehringer expands cancer research at Vienna site Boehringer expands cancer research at Vienna site Boehringer Ingelheim expands cancer research at its Vienna site
12th Expert Forum on Farm Animal Well-Being 12th Expert Forum on Farm Animal Well-Being The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
cystic fibrosis phase II trial cystic fibrosis phase II trial The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Systemic sclerosis - Ilaria's story Systemic sclerosis - Ilaria's story Watch Ilaria talk about her journey living with systemic sclerosis
Mareks Disease Poultry Chicken Mareks Disease Poultry Chicken Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.
Targeting HER2 in cancer: The story of zongertinib Targeting HER2 in cancer: The story of zongertinib We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Outside the lab…inside the family Outside the lab…inside the family We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.